Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies
- PMID: 15358626
- DOI: 10.1182/blood-2004-07-2792
Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies
Abstract
Abnormalities of hemoglobin synthesis are usually inherited but may also arise as a secondary manifestation of another disease, most commonly hematologic neoplasia. Acquired hemoglobin disorders can be seen in any population and are not restricted to areas of the world with high incidences of inherited hemoglobinopathies. In fact, the acquired hemoglobinopathies may be more readily recognized where inherited hemoglobin abnormalities are rare and less likely to cause diagnostic confusion. Acquired alpha-thalassemia is the best characterized of the acquired red blood cell disorders in patients with hematologic malignancy, and it is almost always associated with a myelodysplastic syndrome (MDS). At least 2 molecular mechanisms for acquired alpha-thalassemia are now recognized: acquired deletion of the alpha-globin gene cluster limited to the neoplastic clone and, more commonly, inactivating somatic mutations of the trans-acting chromatin-associated factor ATRX, which cause dramatic down-regulation of alpha-globin gene expression. Here we review the clinical, hematologic, and molecular genetic features of alpha-thalassemia arising in a clonal myeloid disorder, and we discuss howATRX might affect gene expression in normal and abnormal hematopoiesis through epigenetic mechanisms.
Similar articles
-
Deletion of the alpha-globin gene cluster as a cause of acquired alpha-thalassemia in myelodysplastic syndrome.Blood. 2004 Feb 15;103(4):1518-20. doi: 10.1182/blood-2003-09-3222. Epub 2003 Oct 23. Blood. 2004. PMID: 14576055
-
De novo and acquired forms of alpha thalassemia.Curr Hematol Rep. 2006 Mar;5(1):11-4. Curr Hematol Rep. 2006. PMID: 16537041 Review.
-
Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations.Blood. 2004 Mar 15;103(6):2019-26. doi: 10.1182/blood-2003-09-3360. Epub 2003 Oct 30. Blood. 2004. PMID: 14592816
-
A novel 5' ATRX mutation with splicing consequences in acquired alpha thalassemia-myelodysplastic syndrome.Haematologica. 2005 Nov;90(11):1463-70. Haematologica. 2005. PMID: 16266892
-
Understanding alpha-globin gene regulation: Aiming to improve the management of thalassemia.Ann N Y Acad Sci. 2005;1054:92-102. doi: 10.1196/annals.1345.012. Ann N Y Acad Sci. 2005. PMID: 16339655 Review.
Cited by
-
Myelodysplastic syndrome associated with acquired beta thalassemia: "BTMDS".Am J Hematol. 2016 Aug;91(8):E325-7. doi: 10.1002/ajh.24400. Epub 2016 Jul 4. Am J Hematol. 2016. PMID: 27121565 Free PMC article.
-
Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach.Nat Genet. 2011 Mar 20;43(4):295-301. doi: 10.1038/ng.785. Nat Genet. 2011. PMID: 21423179 Free PMC article.
-
Mutant ATRX: pathogenesis of ATRX syndrome and cancer.Front Mol Biosci. 2024 Oct 16;11:1434398. doi: 10.3389/fmolb.2024.1434398. eCollection 2024. Front Mol Biosci. 2024. PMID: 39479502 Free PMC article. Review.
-
Exploring the bone marrow micro environment in thalassemia patients: potential therapeutic alternatives.Front Immunol. 2024 Aug 5;15:1403458. doi: 10.3389/fimmu.2024.1403458. eCollection 2024. Front Immunol. 2024. PMID: 39161767 Free PMC article. Review.
-
A man with polycythemia vera, myelodysplastic syndrome and acquired microcytosis.BMJ Case Rep. 2019 Aug 13;12(8):e229695. doi: 10.1136/bcr-2019-229695. BMJ Case Rep. 2019. PMID: 31413051 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous